Medivir AB Series B | Key People and Executives
Anna Yvonne Monica Malm Bernsten
Chairman
Stig Lennart Hansson
Director
Uli Alf Hacksell
Director
Bengt Westermark
Director
Bengt Åke Julander
Director
Marie Helena Levander
Director
Anna Yvonne Monica Malm Bernsten
Chairman
Christine Lind
President & Chief Executive Officer
Erik Bjork
Chief Financial Officer
Daniel Eriksson
Chief Information Officer
Richard Bethell
Chief Scientific Officer
Christina Elisabeth Herder
Executive VP-Strategic Business Development
Stig Lennart Hansson
Director
Uli Alf Hacksell
Director
Bengt Westermark
Director
Bengt Åke Julander
Director
Marie Helena Levander
Director
Anders R. Hallberg
Director
Åsa Holmgren
Executive VP-Strategic Regulatory Affairs
| Address |
Lunastigen 7
Huddinge AB 141 44
Sweden
|
|
Employees
|
- |
| Website |
http://www.medivir.com |
| Updated |
07/08/2019 |
| Medivir AB engages in the development of pharmaceuticals products. It focuses on the discovery and development of transformative active cancer drugs. Its portfolio includes proprietary pipeline such as remetinostat, birinapant, MV-818, and MIV-711 projects; and partnership pipeline which covers xerclear and MIV-802 project. |
